Durezole, (difluprednate ophthalmic emulsion) is the latest medication developed to treat postoperative eye inflammation and other inflammatory diseases of the eye.
This topically applied ophthalmological anti-inflammatory steroid was approved by the US drug regulatory authority, Food and drog administration (FDA) on June 28, 2008 and Sirion terapeutic Inc, the company that will represent the drug, intends to start its marketing at the end of the same year.
This medication is indicated to reduce inflammation and pain especially in the ophthalmologic postoperative period, reducing the risk of complications and significantly improving the patient's prognosis and recovery.
